Stefan Bernstein explains how the EU/Greenland critical raw materials partnership benefits GreenRoc. Watch the full video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Regulatory News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,708.60
Bid: 1,708.40
Ask: 1,708.80
Change: 0.00 (0.00%)
Spread: 0.40 (0.023%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 1,708.60
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Directorate Change

21 Jul 2017 11:00

RNS Number : 7553L
GlaxoSmithKline PLC
21 July 2017
 

GlaxoSmithKline plc (the "Company")

Board and Committee changes

 

GSK today announces that Dr Laurie Glimcher has been appointed to the Board of the Company as a Non-Executive Director and has been deemed a Scientific and Medical Expert. Dr Glimcher will join the Board on 1 September 2017.

 

Philip Hampton, Chairman of GlaxoSmithKline plc, said: "I am delighted Laurie is joining the Board. Laurie brings a wealth of expertise in scientific and medical innovation and public health which will be invaluable to GSK. "

 

Dr Glimcher is currently Professor of Medicine at Harvard Medical School and is CEO, President and an Attending Physician at the Dana-Farber Cancer Institute.

 

In addition to a number of senior leadership positions held at both Harvard Medical School and Harvard School of Public Health, Dr Glimcher has also served as Stephen and Suzanne Weiss Dean and Professor of Medicine at Weill Cornell Medical College and as an Attending Physician at the New York Presbyterian Hospital/Weill Cornell Medical Center.

 

Dr Glimcher is a member of the Blue Ribbon Panel Advisory Board of the National Cancer Institute and of the American Asthma Foundation. She is a Non-Executive Director of the Parker Institute for Cancer Immunotherapy and of the Waters Corporation, where she also serves on their Corporate Governance Committee. Dr Glimcher recently decided to step down from the Board of Bristol-Myers Squibb Co (BMS) after serving for 20 years on its Board.

 

Dr Glimcher has recently been awarded the Kober Medal from the American Association of Physicians for a lifetime of achievements in the field of internal medicine. She has also received the L'Oreal Laureate Award for her discoveries in immunology, and the Marion Fay Spencer award for her scholarship and commitment to the application of sciences to healthcare. She is also a member of the Lasker Award Jury, a Fellow of the American Academy of Arts and Sciences, a Member of the National Academy of Medicine, a Member of the National Academy of Sciences and a Fellow of the Royal Society of Biology.

 

On joining the Board Dr Glimcher will become a member of the Board's Science and Audit & Risk Committees.

V A Whyte

Company Secretary

21 July 2017

 

Notes

1. As Non-Executive Director of GSK, Dr Glimcher will receive standard annual fees of £85,000 per annum. She will also receive a further £30,000 in respect of her additional duties as a Board Scientific and Medical Expert. To enhance the link between Non-Executive Directors and shareholders, at least 25% of her fees will be paid in the form of Ordinary Shares and allocated to a share account, and she will be able to invest part or all of the balance of her fees into the same share account.

2. The Board has determined that Dr Glimcher will be an independent Non-Executive Director, in accordance with the UK Corporate Governance Code. In addition, the Company confirms that there are no further disclosures to be made in connection with Dr Glimcher's appointment in accordance with Listing Rule 9.6.13R.

3. "Scientific and Medical Expert" - The Board designates Non Executive Directors whose expertise or backgrounds as renowned medical scientists, researchers, or physicians mean that they are able to bring scientific or industry expertise to the Board's deliberations.

4. With effect from 1 September 2017, the composition of the Board of GSK will be as follows:

Sir Philip Hampton

Non-Executive Chairman

Ms Emma Walmsley

Chief Executive Officer

Mr Simon Dingemans

Chief Financial Officer

Dr Patrick Vallance

President, R&D

Professor Sir Roy Anderson

Independent Non-Executive Director

Mr Vindi Banga

Senior Independent Non-Executive Director

Dr Vivienne Cox

Independent Non-Executive Director

Ms Lynn Elsenhans

Independent Non-Executive Director

Dr Jesse Goodman

Independent Non-Executive Director

Dr Laurie Glimcher

Independent Non-Executive Director

Ms Judy Lewent

Independent Non-Executive Director

Mr Urs Rohner

Independent Non-Executive Director

GSK - one of the world's leading research-based pharmaceutical and healthcare companies - is committed to improving the quality of human life by enabling people to do more, feel better and live longer. For further information please visit www.gsk.com.

GSK enquiries:

 

 

 

 

Simon Steel

+44 (0) 20 8047 5502

(London)

 

Eleanor Bunch

+44 (0) 20 8047 5502

(London)

 

 

 

 

US Media enquiries:

Sarah Alspach

+1 202 715 1048

(Washington, DC)

 

Sarah Spencer

+1 215 751 3335

(Philadelphia)

 

 

 

 

Analyst/Investor enquiries:

Sarah Elton-Farr

+44 (0) 20 8047 5194

(London)

 

Tom Curry

+ 1 215 751 5419

(Philadelphia)

 

Gary Davies

+44 (0) 20 8047 5503

(London)

 

James Dodwell

+44 (0) 20 8047 2406

(London)

 

Jeff McLaughlin

+1 215 751 7002

(Philadelphia)

 

Cautionary statement regarding forward-looking statements

GSK cautions investors that any forward-looking statements or projections made by GSK, including those made in this announcement, are subject to risks and uncertainties that may cause actual results to differ materially from those projected. Such factors include, but are not limited to, those described under Item 3.D 'Risk factors' in the company's Annual Report on Form 20-F for 2016.

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
BOAFMGZNLMRGNZG
Date   Source Headline
26th Mar 20243:30 pmRNSDirector/PDMR Shareholding
25th Mar 20241:00 pmRNSNotice of AGM
22nd Mar 20244:20 pmRNSTransfer of Treasury Shares
22nd Mar 20243:36 pmRNSDirector/PDMR Shareholding
18th Mar 20249:30 amRNSNew Phase III Jemperli data in endometrial cancer
13th Mar 20243:48 pmRNSDirector/PDMR Shareholding
8th Mar 20245:12 pmRNSBoard Committee Change
7th Mar 20247:00 amRNSGSK announces positive Blenrep DREAMM-8 results
6th Mar 20244:00 pmRNSViiV LAI vs oral SOC data in adherence-challenged
5th Mar 20245:24 pmRNSGSK Annual Report 2023 on Form 20-F
5th Mar 20247:00 amRNSNew ViiV LA formulation potential 4-month dosing
1st Mar 20243:00 pmRNSTotal Voting Rights
1st Mar 202412:15 pmRNSGSK publishes Annual Report 2023
29th Feb 20247:05 amRNSDirectorate Change
29th Feb 20247:00 amRNSStatement: Zantac (ranitidine) litigation
26th Feb 20243:30 pmRNSDirector/PDMR Shareholding
26th Feb 20247:00 amRNSGSK announces positive EAGLE-1 headline results
22nd Feb 20243:30 pmRNSDirector/PDMR Shareholding
21st Feb 20247:00 amRNSViiV LAI superior to orals in adherence-challenged
20th Feb 20249:01 amRNSJulie Brown - External Appointment
19th Feb 20243:30 pmRNSDirector/PDMR Shareholding
15th Feb 20243:32 pmRNSDirector/PDMR Shareholding
15th Feb 20247:00 amRNSGSK completes acquisition of Aiolos Bio
13th Feb 20244:45 pmRNSDirector/PDMR Shareholding - Replacement
13th Feb 20243:40 pmRNSDirector/PDMR Shareholding
13th Feb 20243:35 pmRNSDirector/PDMR Shareholding
13th Feb 20243:30 pmRNSDirector/PDMR Shareholding
6th Feb 20247:10 amRNSFDA accepts Arexvy filing for adults 50-59 at risk
6th Feb 20247:05 amRNSShingrix 18+ at risk China filing review accepted
6th Feb 20247:00 amRNSGSK presents positive DREAMM-7 phase III data
1st Feb 20243:30 pmRNSDirector/PDMR Shareholding
1st Feb 20243:00 pmRNSTotal Voting Rights
1st Feb 20247:00 amRNSStatement: Zantac (ranitidine) litigation
31st Jan 20247:00 amRNSFinal Results
29th Jan 20247:05 amRNSEMA accepts Arexvy filing for adults 50-59 at risk
29th Jan 20247:00 amRNSEuropean Commission authorises Omjjara in the EU
19th Jan 20243:30 pmRNSDirector/PDMR Shareholding
18th Jan 20245:00 pmRNSHolding(s) in Company
17th Jan 20243:30 pmRNSDirector/PDMR Shareholding
17th Jan 20247:00 amRNSGSK completes sale of shares in Haleon plc
16th Jan 20244:40 pmRNSGSK announces intention to sell shares in Haleon
16th Jan 20243:30 pmRNSDirector/PDMR Shareholding
10th Jan 20247:00 amRNSNucala approved in China for use in severe asthma
9th Jan 20247:00 amRNSGSK enters agreement to acquire Aiolos Bio
2nd Jan 20243:00 pmRNSTotal Voting Rights
21st Dec 20233:30 pmRNSDirector/PDMR Shareholding
20th Dec 20234:44 pmRNSPublication of EMTN Suppl.Prospcts
18th Dec 20237:00 amRNSJemperli plus Zejula Trial Meets Endpoint
13th Dec 20233:30 pmRNSDirector/PDMR Shareholding
12th Dec 20237:00 amRNSJapan accepts Arexvy filing for at risk adults

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.